Bluebird raising $211M; Alimera inks $50M financing deal;

@FierceBiotech: Cyclacel's cancer drug isn't working in Phase III, but that won't stop the trial. Story | Follow @FierceBiotech

@JohnCFierce: Top Monday story: UPDATED: Onyx vet Tony Coles embarks on a new biotech adventure. More | Follow @JohnCFierce

@DamianFierce: Scathing new ad for tightening regs on private equity. Story | Follow @DamianFierce

> Cambridge, MA-based bluebird bio ($BLUE) is raising $211 million through the sale of 2.6 million shares. Release

> Atlanta-based Alimera Sciences inked a $50 million financing deal with Deerfield. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: FDA clears laser-based comb to combat hair loss. Article | Follow @FierceMedDev

@StacyALawrence: GE-backed InSightec gets $59M for noninvasive surgical tool, adds ex-Mako CEO to board. More | Follow @StacyALawrence

@EmilyWFierce: Power morcellator fallout illustrates major flaw in FDA's device regulation. WSJ story | Follow @EmilyWFierce

> Fresenius adds blood purification tech to its dialysis offerings via partnership. Article

> FDA took a back seat in morcellator regulation, researchers say. Report

Pharma News

@FiercePharma: New chief picks team to fuse Actavis with Allergan. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Third round of cuts slated for Novartis US Diovan plant. Total reaches 133 with 394 more gone by 2016. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Baxter backs away from vaccines with Vero tech sale to Nanotherapeutics. More | Follow @CarlyHFierce

> Roche's Lucentis nabs FDA 'breakthrough' tag for diabetic eye disease. More

> FTC plows ahead in pay-for-delay suit over AbbVie's AndroGel. Article

> Fresh off Afinitor failure, Novartis turns tide with Signifor LAR approval. News

Pharma Manufacturing News

> Biocon to build new plant in Vizag, India. Report

> Industry Voices: The future of pharma manufacturing--new disruptive technologies that can impact whole industry structures. More

> Baxter has yet another recall of sodium chloride. News

> Teva continues to whittle down manufacturing network. Story

> Avid Bioservices doubling capacity at its California facility. Article

Biotech Research News

> Scientists look to a pathway in the gut to fix fatty liver disease. Piece

> Repurposed fibroblasts may open the door to new melanoma drugs, screening tech. More

> Investigators hit on a new class of stem cells. Item

> Joslin investigators urge cosmetics groups to get into anti-aging R&D. Article

> NIH's children's health study ends as a $1.2B disaster. Story

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.